【レポートの概要（一部）】
1. Report Overview
1.1 Overview of Findings
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
2. Introduction to Antibacterial Drugs
2.1 Types of Bacterial Infection
2.2 Main Bacteria Causing Infections in Human Beings
2.3 Incidence and Mortality Profiles for Common Bacterial Infection
2.4 Treating Infections
2.4.1 The History of Antibacterial Drug Development
2.4.2 Mechanisms of Action
2.4.3 Leading Classes of Antibacterial Medicines
2.4.3.1 Cephalosporins
2.4.3.2 Penicillins
2.4.3.3 Carbapenems
2.4.3.4 Fluoroquinolones
2.4.3.5 Macrolides
2.4.4 Antibacterial Drug Resistance
3. Antibacterial Drugs: World Market, 2016-2026
3.1 Antibacterials’ Revenues Plateau between 2010 and 2015
3.2 Antibacterial Agents – Market Segmentation
3.3 Antibiotics Market Forecast, 2016-2026: Decline in Revenues for Fluoroquinolones
3.4 Drivers and Restraints in the Antibacterials Market, 2016-2026
3.5 Generic Erosion and Prescription Control will Limit Market Growth
3.6 Changes in that Industry Sector’s Market Shares, 2016-2026
3.7 Pfizer is the Leader in the Antibacterial Drugs Market, 2014
3.8 Fragmented Market to Fracture Further
4. Cephalosporins Market Forecast, 2016-2026
4.1 Cephalosporins Market 2015 – No Dominant Brands
4.1.1 Late-Stage Cephalosporins to Gain Market Share Between 2016 and 2026
4.1.2 Basilea, Merck, Actavis and AstraZeneca to Lead Cephalosporin Market Between 2016 and 2026
4.1.3 Drivers and Restraints on the Cephalosporins Market, 2016-2026
4.1.4 Cephalosporins Lack Market Exclusivity
4.1.5 Strong Pipeline for Novel Cephalosporins
4.1.6 Rocephin (Roche) – The Only Treatment for Gonorrhoea in the US
4.1.6.1 Off Patent but Still Effective
4.1.6.2 Declining Revenues Owing to Competition – Forecast 2016-2026
4.1.7 Sulperazon – India’s Leading Treatment for RTIs and UTIs
4.1.7.1 Continued Growth in the Emerging Markets, Revenue Forecast 2016-2026
4.1.8 Zinnat/Ceftin – GSK’s Established Cephalosporin
4.1.8.1 Continued Decline in Revenue – Forecast 2016-2026
4.1.9 Meiact – A Broad Range Community Antibiotic
4.1.9.1 Spectracef Sales in the US Leads to Pass the Product
4.1.9.2 Competition in Japan to Hinder Growth – Revenue Forecast 2016-2026
4.1.10 Flomox – Shionogi’s Third-Generation Cephalosporin
4.1.10.1 Patent Issues and Litigation
4.1.10.2 Genericisation and Safety to Restrict Sales – Forecast 2016-2026
4.1.11 Zinforo/Teflaro (Ceftaroline Fosamil): The First of the Fifth- Generation Cephalosporins
4.1.11.1 Unmet Needs in Pneumonia to Drive Growth – Revenue Forecast 2016-2026
4.1.12 Zeftera (ceftobiprole): Approved for Pneumonia in Europe
4.1.12.1 Future Sales Dictated by US Approval – Revenue Forecast 2016-2026
4.1.13 CXA-201 (Ceftolozane-Tazobactam): The Next Blockbuster Antibacterial
4.1.13.1 Broad Label and Spectrum of Activity Leads to Rapid Uptake – Revenue Forecast 2016-2026
4.1.14 CAZ-AVI (Ceftazidime-Avibactam): Approved in 2015
4.1.14.1 Competition from CXA-201 to Limit Sales – Forecast 2016-2026
5. Penicillins Market Forecast, 2016-2026
5.1 Generics and Augmentin Dominate the Penicillins Market in 2015
5.2 Augmentin to Lose its Dominance over the Coming 10 Years – Market Shares for Penicillin Drugs, 2016-2026
5.3 Penicillin Antibacterials: Market Forecast 2016-2026
5.4 Drivers and Restraints for the Penicillin Market 2016-2026
5.5 Augmentin – Blockbuster Facing Generic Competition
5.5.1 Augmentin – Challenges in Some Countries
5.5.2 Stable Revenues in Spite of Generic Competition
5.5.3 Revenue Forecast 2016-2026
5.6 Zosyn/Tazocin (Piperacillin-Tazobactam) – Pneumonia Therapeutic
5.6.1 Patent Expiry and Revenue Extension for Pfizer
5.6.2 Historic and Current Revenue Performance
5.6.3 Revenue Forecast 2016-2026
5.7 Unasyn – Gram-negative and Positive Antibiotic
5.7.1 Falling Revenues – Forecast 2016-2026
5.8 Amoxil (Amoxicillin) – A Historic Antibacterial Brand
5.8.1 Marginal Decline in Revenue – Forecast 2016-2026
5.9 Generic Amoxicillin
5.9.1 Revenue Forecast 2016-2026
5.10 Generic Amoxicillin-Clavulanic Acid
5.10.1 Revenue Forecast 2016-2026
6. Fluoroquinolone Market Forecast, 2016-2026
6.1 The Fluoroquinolone Market 2015
6.2 Changing Market Share for Fluoroquinolone Antibacterials, 2016-2026
6.3 Fluoroquinolone Antibacterial Drugs: Market Forecast 2016-2026
6.4 Trends in the Fluoroquinolone Market
6.4.1 Safety Fears for Fluoroquinolones
6.4.2 Avelox Patent Cliff
6.4.3 Inhaled Fluoroquinolone Formulations
6.5 Fluoroquinolone Market Forecast 2016-2026
6.6 Avelox
6.6.1 Safety Profile Hampers Sales
6.6.2 Generic Competition
6.6.3 Revenue Forecast 2016-2026
6.7 Cravit and Levaquin
6.7.1 Generic Competition Affecting Revenue Worldwide
6.7.2 Lifecycle Management for Cravit and Levaquin
6.7.3 Revenue Forecast 2016-2026
6.8 Vigamox
6.8.1 Branded and Generic Challenges 2010-2013
6.8.2 Moxeza: A Next-Generation Form of Vigamox
6.8.3 Revenue Forecast 2016-2026
6.9 Cirpodex and Cipro – Two Preparations of Ciprofloxacin
6.9.1 Ciprodex: A Second-Generation Ophthalmic Antibiotic
6.9.1.1 Revenue Forecast 2016-2026
6.9.2 Cipro Revenue Forecast 2016-2026: Continued Generic Erosion
6.10 Geninax
6.10.1 Revenue Forecast 2016-2026
6.11 Delafloxacin
6.11.1 Revenue Forecast 2016-2026
7. Macrolide Market Forecast, 2016-2026
7.1 Macrolide Market in 2015
7.2 Changing Market Share for Macrolides, 2016-2026
7.3 Macrolide Antibacterials: Market Forecast 2016-2026
7.4 Trends in the Macrolide Market
7.5 Biaxin/Clarith
7.5.1 Past Revenue 2011-2014
7.5.2 Lifecycle Management for Continued Market Presence
7.5.3 Revenue Forecast 2016-2026
7.6 Zithromax
7.6.1 Concerns Over Safety and Marketing in the US
7.6.2 Effectiveness in Drug-Resistant Strains
7.6.3 Revenue Forecast 2016-2026
7.7 Dalacin
7.7.1 Revenue Forecast 2016-2026
7.8 Dificid
7.8.1 Rapid Uptake Slowed by High Cost
7.8.2 New Approvals and Expanded Indications
7.8.3 Revenue Forecast 2016-2026
7.9 Solithromycin
7.9.1 Revenue Forecast 2016-2026
8. Carbapenem Market Forecast, 2016-2026
8.1 Carbapenem Market 2015
8.2 Changing Market Share for Carbapenems, 2016-2026
8.3 Carbapenem Market Forecast, 2016-2026
8.4 Trends in the Carbapenem Market
8.4.1 Rising Prevalence of Carbapenemases and β-Lactamases
8.4.2 No New Carbapenems in Late-Stage Trials
8.5 Merrem/Meropenem
8.5.1 Generics Affecting Revenue Worldwide
8.5.2 Revenue Forecast 2016-2026
8.6 Primaxin
8.6.1 Combination Therapy for Lifecycle Management
8.6.2 Historic and Current Revenues
8.6.3 Revenue Forecast 2016-2026
8.7 Invanz
8.7.1 Revenue Forecast 2016-2026
8.8 Doribax
8.8.1 Doribax in HAP and VAP
8.8.2 Lifecycle Management in Japan and the Rest of the World
8.8.3 Revenue Forecast 2016-2026
9. Other Antibiotic Drugs Forecast, 2016-2026
9.1 The Market for Other Classes of Antibacterial Drugs
9.2 Changing Market Share for Fluoroquinolone Antibacterials 2016-2026
9.3 Other Antibacterials: Market Forecast, 2016-2026
9.4 Trends in the Other Classes of Antibacterial Drugs
9.4.1 New Oxazolidinones Will Drive Growth
9.4.2 New Drug Classes to Drive Submarket Growth to 2026
9.5 Zyvox – The Market Leading Antibacterial
9.5.1 MRSA Activity Driving Revenue Growth
9.5.2 Promise in Tuberculosis and Anthrax
9.5.3 Patents, Litigation, and Competition – When and Who Will Produce Generic Linezolid?
9.5.4 Flat Growth to Patent Expiry, Revenue Forecast 2016-2026
9.6 Cubicin – The Leading Brand for ABSSSIs
9.6.1 Revenue Boosted by Approvals Worldwide
9.6.2 Patents, Litigation and Deals – How Long Will Market Exclusivity Last?
9.6.3 Sustained Growth through to 2020, Revenue Forecast 2016-2026
9.7 Tygacil – A Tetracycline With Many Approved Indications
9.7.1 Concerns Limiting Revenue Potential
9.7.2 Competition from Other Therapies Restricts Growth: Revenue Forecast 2016-2026
9.8 TOBI/TOBI Podhaler – The Market Leading Inhaler for Cystic Fibrosis
9.8.1 Historic and Current Revenue Performance
9.8.2 Approvals and Launches in New Markets to Drive Revenue Growth
9.8.3 Competition to Limit Long-term Growth, Revenue Forecast 2016-2026
9.9 Solodyn – A Treatment for Severe Acne
9.9.1 Generic Competition and Lifecycle Management
9.9.2 Limited Potential for Dermatology, Revenue Forecast 2016-2026
9.10 Vibativ – Limited Potential for Novel Lipoglycopeptide
9.10.1 Astellas Ends its Collaboration with Theravance
9.10.2 Limited HAP Label in the US – Revenue Forecast 2016-2026
9.11 Sirturo – A New Option for Multi-Drug Resistant TB
9.11.1 Chronic Treatment Schedule and Emerging Demand Drive Revenue Growth, Forecast 2016-2026
9.12 Tedizolid – Market Leading Follow-on to Zyvox?
9.12.1 Competition Increasing: Revenue Forecast 2016-2026
9.13 Oritavancin – An Antibiotic With a Novel PK Profile
9.13.1 Single Dose Differentiation to Deliver Market Share (%), Revenue Forecast 2016-2026
9.14 Dalbavancin – Competing in a Crowded Indication
9.14.1 Sustained Growth Over the Coming 10 Years, Revenue Forecast 2016-2026
9.15 Surotomycin –Treatment for C. difficile
9.15.1 Delayed Launch to Limit Potential, Revenue Forecast 2016-2026
9.16 Nemonoxacin – Taiwan’s Global Antibacterial Drug
9.16.1 Slow Initial Growth to Accelerate with US Approval, Revenue Forecast 2016-2026
10. The Leading National Markets, 2016-2026
10.1 US and China Dominate the Global Antibacterial Market, But For Different Reasons
10.2 Above-Average Growth in US: Regional Forecasts, 2016-2026
10.3 China to Slump in Market Share, While Brazil and India Push on
10.4 Incidence of Infection by Country, 2015
10.4.1 Incidence of Pneumonia in National Markets – Pneumonia Predominant in America
10.4.2 Incidence of Community Acquired Urinary Tract Infections in National Markets – High Incidence Rates in the UK, US and Spain
10.4.3 Incidence of Bacterial Skin and Skin Structure Infections in National Markets – High Potential in the US
10.4.4 Incidence of Upper Respiratory Tract Infections in National Markets – Europe Leads the Way
10.5 Antibacterial Drug Consumption by Country, 2015
10.5.1 Antibacterial Drug Consumption in the Major National Markets
10.5.2 Antibacterial Drug Consumption in Some Other National Markets
10.6 The Antibacterials Market in the US
10.6.1 Continued Dominance of the US Market
10.7 The European Union Forms Second Largest Regional Market
10.7.1 Marginal Expansion in Antibacterial Spending – Market Forecast 2016-2026
10.7.2 Action to Encourage Antibacterial Drug Development in the EU
10.7.3 Italy Continues to Lead the Way in Antibiotic Use
10.7.4 The French Fascination with Expensive Antibacterial Drugs
10.7.5 Germany – Europe’s Antibiotic Steward
10.7.6 Rising Use of Antibacterials Drugs in the UK
10.7.7 Spanish Antibacterials Market to Expand from 2020 to 2026
10.8 Japan – Still the Fourth Largest National Market
10.8.1 The Pause Before Growth in the Japanese Market
10.9 Will South Korea Continue Its High Use of Antibiotics?
10.10 BRIC Nation Sales Still Expanding – Market Forecast 2016-2026
10.11 Chinese Antibacterial Market Bloated by Reported Overuse
10.11.1 Developing Antibacterials in China, for China
10.11.2 Governmental Controls Subdue Recent Growth – Market Forecast 2016-2026
10.12 Indian Market to Expand by 50% Over the Forecast Period
10.12.1 Restricting Antibiotic Use in India
10.12.2 Sustained Expansion of the Indian Market, Forecast 2016-2026
10.13 Brazilian Antibacterial Market to Double in Size
10.13.1 Brazilian Market to Be Driven by Drug Resistance
10.14 Russia: TB Prevalence to Stimulate Antibiotic Sales – Forecast 2016-2026
11. Antibacterials R&D Pipeline Review, 2016
11.1 Gram-Positive vs. Gram-Negative
11.2 Pipeline Dominated by Small Molecule Drugs
11.3 Leading Phase III Pipeline Treatment Candidates
11.3.1 Surotomycin – Broad C. difficile Treatment to Reduce Relapse
11.3.2 Tedizolid – More Potent Than Zyvox with Fewer Doses?
11.3.3 Delafloxacin – A Leading pH Activated, Broad Spectrum Fluoroquinolone
11.3.4 Solithromycin – Fluroketolide with Favourable Side Effect Profile
11.3.5 Eravacycline – Treating Gram-Negative cUTIs and cIAIs
11.3.6 Plazomicin – Straight to PIII in Carbapenem Resistant Infections
11.3.7 Cadazolid: Largest PIII C. Difficile Trial
11.3.8 Omadacycline – Another Phase III-Ready Partnership
11.3.9 Relebactam – A Novel β-Lactamase Combination
11.3.10 CEM-102 (Fusidic acid) – Cempra’s Second Pipeline Candidate
11.3.11 BC-3781- Unique Mechanism of Action at 23S?
11.4 Leading Phase II Antibacterial Drug Candidates
11.4.1 AZD5847: An Oxazolidinone for TB
11.4.2 Radezolid – Apparently on Melinta’s Back-Burner for Now
11.4.3 AFN-1252: Highly Specific S. Aureus Antibacterial
11.4.4 TD-1792 – A Russian Antibacterial Medicine
11.4.5 Brilacidin – A Novel Peptide Antibacterial Agent
11.4.6POL7080 – Polyphor and Roche in Multi-Million Dollar Deal
11.5 Inhaled Antibiotics – Advantages in Lung Infections
11.5.1 Cayston: Competition for Novartis?
11.5.2 ARIKACE – Targeting P. aeruginosa
11.5.3 Aeroquin – Better than Podhaler?
11.5.4 BAYQ3939 – Developments for Cystic Fibrosis
11.5.5 NKTR-061: Targeting Intubated Pneumonia
11.5.6 Pulmaquin: A Second Ciprofloxacin Candidate
11.5.7 AeroVanc Targets MRSA Infections
11.5.8 Inhaled Amikacin-Fosfomycin – Adjunctive Therapy for VAP
11.6 Biologics – Truly Novel Antibacterial Therapeutics
11.6.1 MK-3415A: First Antibacterial mAb to the Market?
11.6.2 KB001A – The Leading Antibody Against P. aeruginosa
11.6.3 Aridis Pharmaceuticals: Targeting P. aeruginosa and S. aureus
11.6.4 MEDI4893 – Early Stage mAb to S. Aureus
11.7 Other Classes
11.7.1 AZD0914 – Novel DNA Gyrase Inhibitor
11.7.2 MRX-I – Safer Oral Oxazolidinone to Treat MRSA
11.7.3 GSK2140944 – BTI Class of Antibiotics
11.7.4 Carbavance – to Treat CRE
12. Qualitative Analysis of the Antibacterials Industry and Market, 2016
12.1 SWOT Analysis: Strengths, Weaknesses, Opportunities and Threats Affecting Antibacterials, their Developers, Producers and Marketers
12.2 STEP Analysis: Social, Technological, Economic and Political Forces Affecting the Antibacterial Drug Industry and Market
12.2.1 Social Factors
12.2.2 Technological Developments
12.2.3 Economic Pressures
12.2.4 Political Issues
12.3 Market is Well Established and Demand Will Remain Strong
12.4 High Prevalence of Bacterial Infection Worldwide
12.5 Worldwide Demand for Antibacterials
12.6 Animal Models of Infection are Highly Predictive Compared with Other Therapeutic Fields
12.7 Cutting into a Saturated Market
12.8 Superior Benefit over Generics?
12.9 Resistance – Nature’s Patent Expiry
12.10 Acute Treatment Limits Commercial Potential
12.11 Did Big Pharma Back Away from Antibacterial Drugs?
12.12 Resistance Will Continue to Present New Targets
12.13 First Biologic Antibacterials
12.14 Potential for Smaller Firms to Capitalise
12.15 Developing Preventative Vaccines Rather Than Treatments
12.16 Antibacterial Stewardship Reduces Usage
12.17 Clinical Confusion from Inconsistent Guidance Between Regulatory Bodies
12.17.1 Therapeutic Success in European Clinical Trials
12.17.2 Primary End Points in FDA Guidelines
12.18 Reduction in Hospital Infection Rates – Reducing Demand for Antibacterial Drugs
12.19 Enticing Antibacterial Drug Discovery – Push and Pull Incentives
12.19.1 GAIN act: Post-Development Pull Incentives in the US
12.19.2 ADAPT – Building on the GAIN act
12.19.3 EMA Update Guideline – Streamlining Clinical Trials in the EU
12.19.4 Push Incentives for Antibacterial Drug Discovery with Public Funding
12.19.5 IMI: Public-Private Collaboration with GSK and AstraZeneca
12.19.6 Public Finance Pumping Money into Antibacterial Development
13. Research Interviews from Our Survey
13.1 Dr. Holger Zimmermann, Chief Executive Officer (CEO) of AiCuris Anti-infective Cures GmbH
13.1.1 AiCuris Anti-infective Cures GmbH
13.1.2 Introduction
13.1.3 Antibacterial Drugs Market – What Dynamic Have You Observed?
13.1.4 Antibacterial Drugs Market – Drivers and Restraints
13.1.5 What Technological Advances Will Benefit the Antibacterial Drugs Market?
13.1.6 The Burden of Carbapenem-resistant organisms in Germany
13.1.7 AiCuris – Present Development Status of AIC499
13.2 Dr Bruce R. Donald (Duke University), Dr Amy C. Anderson (University of Connecticut), and Mr. Pablo Gainza-Cirauqui (Duke University)
13.2.1 OSPREY
13.2.2 OSPREY – Specializes in Accurate Negative Design
13.2.3 Technical Challenges in Predicting Mutations
13.2.4 Success Rate – Top Four Predictions Confirmed in vitro
13.2.5 OSPREY Could Potentially Predict Resistance Mutations to Biologics (mAbs)
13.2.6 Further Work: Optimize Antibody for Highest in vivo Efficacy
13.2.7 Anticipate Mutations – Redesign Drugs to Maximize Effective Lifespan
14. Antibacterial Drugs Market to 2026: Conclusions
14.1 Three Blockbuster Antibacterials in 2015, Leading Brands
14.2 The Leading Branded Antibacterial Drugs in 2026
14.3 Signs of Life in the Antibacterial R&D Pipeline
14.4 Stemming the Tide of Antibacterial Drug Resistance
14.5 The Changing Face of Antibacterial Clinical Development
Appendices
Some Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
【レポート販売概要】
■ タイトル：抗菌薬の世界市場：セファロスポリン、ペニシリン、フルオロキノロン、マクロライド系薬、カルバペネム系薬■ 英文：Antibacterial Drugs: World Industry and Market Prospects 2016-2026
■ 発行日：2016年3月
■ 調査会社：visiongain
■ 商品コード：VGAIN6041536
■ 調査対象地域：グローバル
- アジア太平洋の無段変速機（CVT）システム市場2016-2020About Continuously Variable Transmissions Systems Transmission is a key function of powertrains in automotive vehicles. A vehicle's transmission is a type of gearbox that directs the power generated from an internal combustion engine to the wheel axle. Typically, an automotive transmission system includes the entire drivetrain, which comprises components such as a gearbox, clutch, prop shaft, driv …
- ロボット塗装ブースの世界市場2017-2021：塗装ブース、塗装ロボットAbout Robotic Paint Booth Almost every machine, ranging from a small component to an aircraft, requires a coat of paint over the metallic surface to protect it from corrosion. It is this need that makes manufacturers to adopt automated painting technologies in their facilities to ensure health safety of workers, improve throughput, and enhance process efficiency. Automated systems like paint robot …
- 微生物検査の世界市場2017-2021ABSTRACTAbout Microbiology Testing Microbiological tests are conducted to study the various types of microbes such as bacterial, yeast, fungi, and viruses and their effects on an individual. Microbial testing products provide a wide array of experimental approaches for the diagnosis of infections. Microbiological testing helps detect the presence of pathogenic microorganisms and their metabolites …
- 重症急性呼吸器症候群(SARS)コロナウイルス感染症(SARS Coronavirus Infection)：世界の治験レビュー2014年下半期版Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Global Clinical Trials Review, H2, 2014" provides data on the Severe Acute Respiratory Syndrome (SARS) clinical trial scenario. This report provides elemental information and data relating …
- ヨット用バッテリーの世界市場2017-2021About Yacht BatteryYachts are recreational boats designed with luxury amenities, and are purchased by individuals belonging to the high-income group. Yachts with a length greater than 24 feet are known as luxury yachts, superyachts, mega yachts, or large yachts. They are segmented based on size and propulsion, and are largely used for recreational purposes. The global yacht battery market is mainl …
- Sumavel DosePro (片頭痛/Migraine)：医薬品市場予測及び分析（～2023）Sumavel DosePro (Migraine) - Forecast and Market Analysis to 2023 Summary The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature pr …
- 次世代がん診断の世界市場の規模と予測：技術別（NGS、LOACおよびRT-PCR）、用途別（CTC、バイオマーカー）、がん別（肺、乳房）、機能コンパニオン診断別、動向分析、2013-2024The global next generation cancer diagnostics market is anticipated to reach USD 11.04 billion by 2024, according to a new report by Grand View Research, Inc. Key drivers for this vertical include rising advancement in genomics and proteomics-based research coupled with increasing prevalence of oncology disorders. Rise in number of oncological research projects to elucidate tumorigenesis and the u …
- 農業用微量栄養素の世界市場2016-2020About Agricultural Micronutrients Agricultural micronutrients are vital nutrients, which are required in trace amounts, to control certain physiological activities in crops to increase the yield and improve quality. The deficiency of these micronutrients causes deterioration in the growth rate, withering of buds, and yellowing of leaves in crops. Molybdenum, manganese, boron, zinc, copper, and iro …
- 企業VSATの世界市場2015-2019[Global Enterprise VSAT Market 2015-2019] Covering: Market forecast and growth prospects for enterprise VSAT until 2019. Market segmentation by hardware and services include ASP VSAT terminals and ARUP VSAT terminals. Market shares for APAC, Americas, and EMEA. The leading vendors analyzed by this report include Gilat Satellite, Hughes, SageNet, ViaSat, and VT iDirect. [Market outlook of VSAT for …
- 世界のスケール防止剤市場：ホスホン酸系、カルボン酸/アクリル系、スルホン酸系スケール防止剤Scale inhibitor (antiscalants) are chemical substances that, when added to industrial water at very low levels, act to reduce or prevent the formation of scale. They can be classified into phosphonates, carboxylate/acrylic, sulfonates, and others. Scale inhibitor are widely preferred nowadays across different industries that include power & construction, mining, oil & gas, water & waste water trea …
- 脈絡膜新生血管治療薬の世界市場2016-2020About Choroidal Neovascularization Choroidal neovascularization is the formation of new blood vessels in the choroid layer of the eye. These vessels grow through the Bruch membrane into the subretinal space, blocking the proper functioning of retina and leading to vision loss. The condition is often associated with myopia, malignant myopic degeneration, or age-related macular degeneration (AMD). T …
- 携帯型クーラーの世界市場2019-2023Global Portable Coolers Market: About this market A portable cooler helps users to preserve foods and beverages from perishing. Technavio’s portable coolers market analysis considers sales from hard-sided and soft-sided and other products. Our analysis also considers the sales of portable coolers in APAC, Europe, MEA, North America, and South America. In 2018, the hard-sided segment had a signific …
- エトキシレートの世界市場：アルコール、脂肪族アミン、メチルエステル、グリセリド・エトキシレートThe market for ethoxylates is estimated to grow on account of the increasing surfactants, and household & personal care market. The shift in lifestyles of consumers in major developing economies is also a major driving factor of the ethoxylates market. The factors restraining the market growth are low demand in developed nations and environmental regulations regarding the use of ethoxylates. The e …
- 調達アウトソーシングサービスの世界市場展望2017-2026According to Stratistics MRC, the Global Procurement Outsourcing Services market is accounted for $2856.72 billion in 2017 and is expected to reach $9437.63 billion by 2026 growing at a CAGR of 14.2% during the forecast period. The need to adhere to regulatory guidelines and ensure compliance and emergence of nearshore and offshore outsourcing locations are some key factors propelling the growth o …
- アルミニウム製熱シールドの世界市場Aluminum heat shield market projected to reach USD 1.02 billion by 2021The global aluminum heat shield market is projected to reach USD 1.02 billion by 2021, at a CAGR of 4.5% from 2016 to 2021. Increasing vehicle production across the globe is one of the factors driving the growth of the aluminum heat shield market. Rising concern towards safety in automotive and firearms is another factor that h …
